Previous findings by our laboratory had implicated HER2 and BCRP in resistance to the growth inhibitory effects of letrozole and to maintenance of stem cell characteristics in letrozole-resistant breast cancer, and had demonstrated that its expression was dependent on HER2[35,52], but it was unclear until now how HER2 regulated BCRP. Here, ERBB2 is linked to breast carcinoma.